Dr. Cameron Turtle is an experienced leader in building, financing, and shaping biopharma organizations from preclinical development to late-stage clinical trials and commercialization. Dr. Turtle joined Aeglea as Chief Commercial Officer prior to the acquisition of Spyre Therapeutics. Previously, he served as Venture Partner at Foresite Labs as well as Chief Strategy Officer of BridgeBio Pharma. Prior to BridgeBio, Dr. Turtle was the Chief Business Officer of Eidos Therapeutics, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for heart failure. Prior to joining Eidos, he was a consultant at McKinsey & Company, where he worked with pharmaceutical and medical device companies on topics including M&A, growth strategy, clinical trial strategy, and sales force optimization. Dr. Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in cardiovascular medicine from the University of Oxford, St. John’s College. He is the recipient of several awards, including a Rhodes Scholarship, a Goldwater Scholarship, Forbes 30 Under 30, San Francisco Business Times 40 Under 40, and the Biocom Life Sciences Catalyst Award.